Madrigal Pharmaceuticals says its NASH drug, resmetirom, has met its early endpoints in a Phase III trial, marking a major success in a field littered with failures in recent years. Now, the company plans to submit for accelerated approval in the first half of next year, CEO Paul Friedman said in a statement.
The biotech’s stock $MDGL was up over 200% in pre-market trading, eclipsing the $200 mark. It had closed at just under $64 on Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,700+ biopharma pros reading Endpoints daily — and it’s free.